Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Elementis profits grow in Q1

(Sharecast News) - Chemicals business Elementis said on Tuesday that both profit growth and margin improvement were in line with expectations during a "solid" Q1. Elementis said it had delivered a strong performance despite a "weak global demand environment", with adjusted operating profit and margins both ahead of Q1 FY2024, driven by continued progress of its self-help initiatives, including pricing.

Personal care sales in the quarter were marginally up on a constant currency basis, while cosmetics were broadly flat despite soft demand in Asia and a weaker mix. Performance specialties sales, on the other hand, were "modestly lower" on a constant currency basis compared to Q1 last year.

The FTSE 250-listed group also noted that cash generation in the first quarter was in line with expectations.

Chief executive Luc van Ravenstein said: "We have delivered a solid performance with growth in profitability and margins in what has been a challenging demand environment. Looking ahead, we are well positioned to manage the potential impacts of the recent US tariffs due to our global multi-site manufacturing footprint. However, the future demand impacts are highly uncertain. To help mitigate this, we are making strong progress with our self-help actions, and are on-track to achieve our target of $12m savings this year, with additional savings opportunities being identified. Whilst we are mindful of the increased economic uncertainty associated with tariffs, our expectations for the full year are unchanged."

Looking ahead, van Ravenstein added that Elementis was continuing to make "good progress" towards its 2026 goals and was building on its "strong foundations" to take the business "to the next level".

As of 0850 BST, Elementis shares were up 0.78% at 129.40p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.